Dual blockades of TIM-3 and PD-1 effectively prevent hyper-progression and enhance the efficacy of anti-PD-1 therapy in high-grade serous ovarian cancer. This evidence concerns the gene HAVCR2 and ovarian serous adenocarcinoma.